Recombinant Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (F(ab')2-scFv2) is designed to be expressed as two chains combined via a hinge region. The scFv of the anti-CD2 specificity is fused to the C terminus of the anti-TCR (Vβ8) Fab fragment, or vice versa. This format comprises four binding sites (two same scFv regions and two same Fab fragments), two for each antigen. This BsAb can activate T cells. It is designed for the research of Tumors therapy.